Product
CYP17 Lyase Inhibitor
PHARMACEUTICAL
byInnocrin Pharmaceuticals, Inc.
United States (US)
ABOUT THE PRODUCT
A novel, oral CYP17 lyase inhibitor under development for the treatment of castration-resistant prostate cancer.
Information is owner-confirmed
Last updated 3 weeks ago
Price range